MARK2 and neoplasm: Sorafenib is a multikinase inhibitor that can inhibit tumor cell proliferation and angiogenesis through the inactivation of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-kit receptor, and the serine-threonine kinase Raf-1 [130].